HSBC Adjusts Price Target on Intuitive Surgical to $392 From $391
HSBC has updated its price target for Intuitive Surgical, Inc., raising it slightly from $391 to $392.
Stocks · News reference
IEEE Designates First Robotic Telepresence Surgery System as an IEEE Milestone
The IEEE has officially recognized the "First Robotic Telepresence Surgery System," the technology licensed to Intuitive Surgical that became the da Vinci Surgical System, as an IEEE Milestone.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up
Revvity (RVTY) reported Q3 2026 adjusted EPS of $1.38, beating estimates by 7%, with revenues rising 4.3% to $728.9M. Life Sciences revenues climbed 10.7% driven by strong pharma and biotech demand. The company raised its 2026 pro forma EPS guidance to $5.40-$5.45 and revenue forecast to $2.86B, reflecting 6% total growth and 5% organic growth.
Intuitive Surgical Executive Fredrik Widman Executes Stock Options and Sells Shares
Fredrik Widman, Corporate Vice President and Financial Controller at Intuitive Surgical, exercised stock options and sold 5,448 shares of company stock.
Intuitive Surgical Appoints Aaron Martin to Board of Directors
Intuitive Surgical has announced the appointment of Humana executive Aaron Martin to its board of directors, effective January 1, 2027.
8-K filing — INTUITIVE SURGICAL INC (ISRG)
Filed: 2026-11-02 AccNo: 0001035267-26-000074 Size: 164 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.